department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Onpattro · pharmadog

pharmadog
drugs
Onpattro

drug

patient view →

patisiran

Marketedupdated 2mo ago

by $ALNY ALNYLAM PHARMACEUTICALS, INC.

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Onpattro

generic

patisiran

indication

Familial Amyloid Neuropathies

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 3, 2027

~1.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (13)

Aug 27, 2035compositionUS 11079379
Aug 10, 2032compositionUS 8168775
Nov 10, 2030formulationUS 81586014.3y
Oct 21, 2030formulationUS 88026444.3y
Oct 20, 2029compositionUS 102401523.3y
Oct 20, 2029method-of-use (U-2378)US 87418663.3y
Oct 20, 2029formulationUS 92341963.3y
Apr 15, 2029formulationUS 111413782.8y
Apr 15, 2029formulationUS 80580692.8y
Apr 15, 2029formulationUS 84923592.8y
Apr 15, 2029formulationUS 88226682.8y
Apr 15, 2029formulationUS 93644352.8y
Oct 3, 2027formulationUS 86420761.2y

FDA exclusivities (1)

Jan 13, 2026M-270Method (3y)

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying patisiran

phase3APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)completedn=360
EP1Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapyactive not recruitingn=10
phase3HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)completedn=164
—Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)approved for marketing
phase3APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosiscompletedn=225
phase3Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplantcompletedn=24
phase2Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosiscompletedn=29
phase2The Study of ALN-TTR02 (Patisiran) for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)completedn=27

more trials →